Endocannabinoid system and cardiometabolic risk.
The increasing prevalence of overweight and obesity counteracts the favorable advances of risk factor management achieved for cardiovascular disease (CVD) prevention. Obese and overweight individuals are at increased risk for CVDs and diabetes mellitus, a risk pattern called "cardiometabolic risk." There is a growing interest concerning the role of the endocannabinoid system in energy metabolism and how blockade of cannabinoid receptors (CB(1)) may optimize fat distribution, insulin sensitivity, and blood lipids to improve cardiovascular risk profile.
Saavedra
L E
LE
General Cardiology & Coronary Care Unit Services, CCR ASCARDIO, Barquisimeto, Venezuela. leonardosaavedra@intercable.net.ve
D050153:Abdominal Fat / Q000378:metabolism; D054392:Adipokines / Q000378:metabolism; D000818:Animals; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism*; D048909:Diabetes Complications / Q000209:etiology / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000209:etiology / Q000378:metabolism; D063388:Endocannabinoids; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D009765:Obesity / Q000150:complications / Q000378:metabolism*; D050177:Overweight / Q000150:complications / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000077285:Rimonabant; D015431:Weight Loss / Q000187:drug effects
D054392:Adipokines; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D008055:Lipids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant